Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.

[1]  R. Herbst,et al.  Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Minna,et al.  AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells , 2022, Cell reports. Medicine.

[3]  H. Son,et al.  Immune Evasion Mechanism and AXL , 2021, Frontiers in Oncology.

[4]  J. Nieva,et al.  Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. , 2021, Journal of Clinical Oncology.

[5]  M. Horinaka,et al.  ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[6]  R. Brekken,et al.  Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers , 2019, Front. Oncol..

[7]  B. Halmos,et al.  Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer , 2019, Translational cancer research.

[8]  E. Schmidt,et al.  MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC , 2019, Journal of Thoracic Oncology.

[9]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[10]  S. Yano,et al.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.

[11]  R. Holt,et al.  Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS , 2018, Blood.

[12]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[13]  Yan Li,et al.  Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models , 2017, Oncotarget.

[14]  W. De,et al.  Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer , 2017, Oncotarget.

[15]  L. Byers,et al.  Axl Receptor Axis: A New Therapeutic Target in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  T. Mitsudomi,et al.  Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression , 2016, PloS one.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[19]  S. Chuang,et al.  Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. , 2013, Free radical biology & medicine.

[20]  M. Sonobe,et al.  Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients , 2012, Annals of Surgical Oncology.

[21]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[22]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[23]  H. Earp,et al.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors , 2010, Expert opinion on therapeutic targets.

[24]  Y. Chu,et al.  Expression of axl in lung adenocarcinoma and correlation with tumor progression. , 2005, Neoplasia.

[25]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.